Facebook Linkedin RSS Twitter Youtube
Home 2024

Nvidia

StockWatch: Nvidia’s $3T Market Cap, Tempus’ $400M IPO Reflect AI Allure
Artificial Intelligence

StockWatch: Nvidia’s $3T Market Cap, Tempus’ $400M IPO Reflect AI Allure

Sartorius Expands Drug Discovery and Biomanufacturing Deal with NVIDIA
Bioprocessing

Sartorius Expands Drug Discovery and Biomanufacturing Deal with NVIDIA

Recursion Completes Supercomputer for AI Drug Discovery
Artificial Intelligence

Recursion Completes Supercomputer for AI Drug Discovery

StockWatch: Biogen Q1 Results Beat Expectations, for a Change
Drug Discovery

StockWatch: Biogen Q1 Results Beat Expectations, for a Change

At Bio-IT World 2024, AI Applications Take Center Stage
Artificial Intelligence

At Bio-IT World 2024, AI Applications Take Center Stage

AACR 2024: Aviv Regev Shows How Single-Cell Atlases Foster New Axis to Genentech’s Drug Discovery
Artificial Intelligence

AACR 2024: Aviv Regev Shows How Single-Cell Atlases Foster New Axis to Genentech’s Drug Discovery

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
Artificial Intelligence

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

GTC 2024: Nvidia’s Quantum Expansion Runs through the Cloud
Artificial Intelligence

GTC 2024: Nvidia’s Quantum Expansion Runs through the Cloud

GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics
Artificial Intelligence

GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics

StockWatch: Nvidia Shares Leap Again after Reporting Record Revenues
Artificial Intelligence

StockWatch: Nvidia Shares Leap Again after Reporting Record Revenues

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.